Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.

The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.